What is Sarepta Therapeutics Inc. (SRPT) Price Targets?

0
9

Sarepta Therapeutics Inc. (NASDAQ:SRPT) saw an upside of 0.03% to close Tuesday at $128.37 after adding $0.04 on the day. The 5-day average trading volume is 896,120 shares of the company’s common stock. It has gained $133.47 in the past week and touched a new high 2 times within the past 5 days. An average of 964,355 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 900,680.

SRPT’s 1-month performance is -2.31% or -$1.58 on its low of $116.10 reached on 01/09/23. The company’s shares have touched a 52-week low of $61.28 and high of $134.08, with the stock’s rally to the 52-week high happening on 01/24/23. YTD, SRPT has lost -0.93% or -$1.21 and has reached a new high 5 times. However, the current price is down -4.26% from the 52-week high price.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Insider Transactions

SRPT stock investors last saw insider trading activity on Nov 17.Mayo Stephen (Director) most recently sold 858 shares at $109.92 per share on Nov 17. This transaction cost the insider $94,311.

Valuation Metrics

SRPT stock has a beta of 1.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 12.62 while the price-to-book (PB) in the most recent quarter is 26.09.

Sarepta Therapeutics Inc.’s quick ratio for the period ended September 29 was 4.00, with the current ratio over the same period at 4.40. As well, the company’s long term debt to equity for the quarter ending September 29 was 3.58, while the total debt to equity was 3.58.. In terms of profitability, the gross margin trailing 12 months is 83.90%. The firm’s gross profit as reported stood at $604.84 million against revenue of $701.89 million.

Earnings Surprise

For the quarterly period ending September 29 this year, Sarepta Therapeutics Inc.’s cash and short-term investments amounted to $1.03 billion against total debt of $1.6 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 81.32% to -$257.74 million, while revenue of -$231.48 million was 10.19% off the previous quarter. Analysts expected SRPT to announce -$1.43 per share in earnings in its latest quarter, but it posted -$2.94, representing a -105.60% surprise. EBITDA for the quarter stood at more than -$120.65 million. SRPT stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 2.73 billion, with total debt at $1.6 billion. Shareholders hold equity totaling $87.78 million.

Let’s look briefly at Sarepta Therapeutics Inc. (SRPT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 57.34% to suggest the stock is trending Neutral, with historical volatility in this time period at 25.76%.

The stock’s 5-day moving average is $128.69, reflecting a -1.25% or -$1.63 change from its current price. SRPT is currently trading -2.85% above its 20-day SMA, +17.44% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +23.50% and SMA200 by+45.66%.

Stochastic %K and %D was 78.96% and 79.96% and the average true range (ATR) pointed at 4.47. The RSI (14) points at 56.72%, while the 14-day stochastic is at 70.64% with the period’s ATR at 4.47. The stock’s 9-day MACD Oscillator is pointing at 2.10 and 4.16 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Sarepta Therapeutics Inc. (NASDAQ: SRPT), BTIG Research reiterated its a Buy rating for the company but lifted their price target by $125 to $160. Analysts offering their rating for SRPT stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate SRPT as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 15 have offered a “buy” rating.

What is SRPT’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $108.00 and a high of $195.00, with their median price target at $152.50. Looking at these predictions, the average price target given by analysts is for Sarepta Therapeutics Inc. (SRPT) stock is $149.75.

LEAVE A REPLY

Please enter your comment!
Please enter your name here